false
Catalog
2023 World Conference on Lung Cancer (Posters)
EP11.01. Does Tumor Microvessel Density Predict Re ...
EP11.01. Does Tumor Microvessel Density Predict Response to Immune Checkpoint Inhibitors in Metastatic Non Small Cell Lung Cancer? - PDF(Abstract)
Back to course
Pdf Summary
This presentation at WCLC 2023 explored the potential of microvessel density (MVD) as a biomarker for predicting response to immune checkpoint inhibitors (ICIs) in metastatic non-small cell lung cancer (NSCLC). The study included 49 patients with metastatic NSCLC who received second-line treatment, with 26 patients receiving immunotherapy and 23 receiving chemotherapy. MVD was assessed using immunohistochemistry staining for CD34, and patients were classified into two groups based on the mean MVD value.<br /><br />The results showed that in the immunotherapy arm, patients with an MVD score of 15 had better progression-free survival (PFS) and overall survival (OS) compared to those with an MVD score of 15. The median PFS was 15 months for the MVD score 15 group, compared to 5 months for the MVD score 15 group. The median OS was 43 months for the MVD score 15 group, compared to 9 months for the MVD score 15 group. No correlation was found between PD-L1 expression and PFS or OS in the immunotherapy group.<br /><br />These findings suggest that assessing MVD score in tumor tissue could potentially serve as a useful marker for predicting treatment response to ICIs in patients with metastatic NSCLC. Further research and validation of these results may help improve patient selection for immunotherapy and optimize treatment strategies for NSCLC patients.
Asset Subtitle
Akif Turna
Meta Tag
Speaker
Akif Turna
Topic
Metastatic NSCLC: Immunotherapy - Biomarker
Keywords
microvessel density
biomarker
predicting response
immune checkpoint inhibitors
metastatic non-small cell lung cancer
second-line treatment
immunotherapy
chemotherapy
progression-free survival
overall survival
×
Please select your language
1
English